Literature DB >> 18605972

Side effects of angiotensin converting enzyme inhibitor (captopril) in newborns and young infants.

Monika Herbst Gantenbein1, Urs Bauersfeld, Oskar Baenziger, Bernhard Frey, Thomas Neuhaus, Felix Sennhauser, Vera Bernet.   

Abstract

AIM: To analyze the side effects of captopril, an angiotensin converting enzyme inhibitor (ACEI) in newborn and young infants.
METHODS: Retrospective analysis of side effects in 43 patients with congenital heart disease after cardiac surgery treated with captopril for heart failure during a two-year period.
RESULTS: Median age of the patients was 26 days (range 6-310 days), median weight 3.5 kg (range 1.9-7.9 kg). Initial median dose of captopril was 0.17 mg/kg/day (range 0.05-0.55 mg/kg/day), slowly increased over 3-33 days to a maximal median dose of 1.86 mg/kg/day (range 0.2-2.3 mg/kg/day). All patients were additionally treated with diuretics. Side effects occurred in 17 patients (renal impairment or failure in 6, low blood pressure in 8, and oxygen saturation deficit in 3) requiring cessation or interruption in seven patients with renal impairment/failure (n=4), hypotension (n=1) and aorto-pulmonary shunting with low pulmonary perfusion (n=2). The six children who developed renal impairment or failure did so following a median delay of nine days after reaching the final dose and weighed on average 500 g less than the other patients (P=0.046). All side effects were fully reversible.
CONCLUSION: Side effects due to captopril were not dose-related in newborns and infants in this study. However, renal side effects occurred more often in smaller infants. Routine monitoring of infants on ACEI should include renal function tests, blood pressure and transcutaneous oxygen saturation measurements.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18605972     DOI: 10.1515/JPM.2008.064

Source DB:  PubMed          Journal:  J Perinat Med        ISSN: 0300-5577            Impact factor:   1.901


  9 in total

1.  Translating clinical trials into clinical practice: a survey assessing the potential impact of the Pediatric Heart Network Infant Single Ventricle Trial.

Authors:  Victor Zak; Daphne T Hsu; Victoria L Pemberton; Jami C Levine; Andrew M Atz; James F Cnota; Chitra Ravishankar; Piers Barker; Linda M Lambert; Brian W McCrindle; Michele A Frommelt; Karen Altmann; Shan Chen; Richard V Williams
Journal:  Cardiol Young       Date:  2017-02-10       Impact factor: 1.093

2.  Angiotensin Converting Enzyme Inhibitor (ACEI)-Induced Acute Renal Failure in Premature Newborns with Congenital Heart Disease.

Authors:  Grace J Lee; Risa Cohen; Anthony C Chang; John P Cleary
Journal:  J Pediatr Pharmacol Ther       Date:  2010-10

3.  Acute kidney injury after cardiac surgery in infants and children: evaluation of the role of angiotensin-converting enzyme inhibitors.

Authors:  Christina M Phelps; Jennifer Eshelman; Eduardo Da Cruz; Zhaoxing Pan; Jon Kaufman
Journal:  Pediatr Cardiol       Date:  2011-07-29       Impact factor: 1.655

4.  Variation in captopril formulations in pharmacies across Canada.

Authors:  Mihir Dipakkumar Bhatt; Jason E Thomas; Tapas Kumar Mondal
Journal:  Paediatr Child Health       Date:  2011-04       Impact factor: 2.253

Review 5.  Hypertensive crisis in children.

Authors:  Jayanthi Chandar; Gastón Zilleruelo
Journal:  Pediatr Nephrol       Date:  2011-07-20       Impact factor: 3.714

6.  Angiotensin-converting enzyme inhibitor nephrotoxicity in neonates with cardiac disease.

Authors:  Katherine A Lindle; Kim Dinh; Brady S Moffett; W Buck Kyle; Natalie M Montgomery; Susan D Denfield; Jarrod D Knudson
Journal:  Pediatr Cardiol       Date:  2014-03       Impact factor: 1.655

Review 7.  Drug-induced acute kidney injury in neonates.

Authors:  Mina H Hanna; David J Askenazi; David T Selewski
Journal:  Curr Opin Pediatr       Date:  2016-04       Impact factor: 2.856

8.  Orodispersible minitablets of enalapril for use in children with heart failure (LENA): Rationale and protocol for a multicentre pharmacokinetic bridging study and follow-up safety study.

Authors:  Milica Bajcetic; Saskia N de Wildt; Michiel Dalinghaus; Jörg Breitkreutz; Ingrid Klingmann; Florian B Lagler; Anne Keatley-Clarke; Johannes Mpj Breur; Christoph Male; Ida Jovanovic; Andras Szatmári; László Ablonczy; Bjoern B Burckhardt; Willi Cawello; Karl Kleine; Emina Obarcanin; Lucie Spatenkova; Vanessa Swoboda; Marijke van der Meulen; Peter Wagner; Jennifer Walsh; Stephanie Läer
Journal:  Contemp Clin Trials Commun       Date:  2019-06-08

9.  Human liver rate-limiting enzymes influence metabolic flux via branch points and inhibitors.

Authors:  Min Zhao; Hong Qu
Journal:  BMC Genomics       Date:  2009-12-03       Impact factor: 3.969

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.